Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P {6-11} J.D. Jonkman-de VriesH. RosingJ.H. Beijnen OriginalPaper Pages: 99 - 111
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units Lillian L. SiuDaniel D. Von HoffS. Gail Eckhardt OriginalPaper Pages: 113 - 119
Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs Tomohiro NodaTomoyuki WatanabeTadashi Suzuki OriginalPaper Pages: 121 - 128
Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate Thomas H. CorbettPatricia LoRussoGeorge Trainor OriginalPaper Pages: 129 - 139
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study Diana LüftnerBernd FlathKurt Possinger OriginalPaper Pages: 141 - 146
Phase I and pharmacokinetic study of intraperitoneal topotecan Steven C. PlaxeRandolph D. ChristenStephen B. Howell OriginalPaper Pages: 147 - 153
Phase I/II evaluation of Pentostatin (2′-deoxycoformycin) in a five day schedule for the treatment of relapsed/refractory B-cell chronic lymphocytic leukaemia S.A. JohnsonD. CatovskyR. Janmohamed OriginalPaper Pages: 155 - 160
A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck Jonathan J. BeitlerRichard V. SmithScott Wadler OriginalPaper Pages: 161 - 169
Phase II trial of oral β-all trans-retinoic acid in hepatocellular carcinoma (SWOG 9157) Frank L. Meyskens Jr.Joth JacobsonJohn S. MacDonald OriginalPaper Pages: 171 - 173
Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma Jaffer A. AjaniRichard PazdurJackie Fairweather OriginalPaper Pages: 175 - 177
Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer Martin J. EdelmanFrederick J. MeyersJames Doroshow OriginalPaper Pages: 179 - 182
Phase II study of paclitaxel (BMS-181339) intravenously infused over 3 hours for advanced or metastatic breast cancer in Japan Yoshinori ItoNoboru HorikoshiMakoto Ogawa OriginalPaper Pages: 183 - 190
Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial Robert S. WitteJudith ManolaPatrick J. Loehrer Sr. OriginalPaper Pages: 191 - 195